首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1542594

全球紅色生物技術市場研究報告 - 2024年至2032年行業分析、規模、佔有率、成長、趨勢和預測

Global Red Biotechnology Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 129 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球紅色生物技術市場需求預計將從2023年的6,047.2億美元達到近1,5,393.9億美元的市場規模，2024-2032年研究期間複合年成長率為10.94%。

紅色生物技術，也稱為醫療生物技術，是生物技術的一個分支，專注於藥品、醫療器材、診斷和醫療保健解決方案。與綠色生物技術（農業生物技術）和白色生物技術（工業生物技術）不同，它主要針對醫療和保健應用。它涉及使用生物過程、有機體或系統來開發產品和技術來診斷、預防和治療疾病並改善整體醫療保健結果。

市場動態

在全球慢性病和傳染病患者病率上升的推動下，全球紅色生物技術市場正在顯著成長。紅色生物技術對於開發創新療法、疫苗和診斷工具至關重要，以應對與癌症、糖尿病、心血管疾病和 COVID-19 等傳染病相關的醫療保健挑戰。此外，基因組研究、個人化醫療和生物製藥的進步正在推動市場成長。基因編輯、重組 DNA 技術和單株抗體等技術可實現針對性和客製化的醫療保健方法，從而提高治療效果和患者預後。

此外，製藥公司、學術機構和政府組織對研發（R&D）的投資不斷增加，推動了紅色生物技術的創新。這些投資支持發現新的候選藥物、疾病診斷的生物標記以及利用生物技術進步的突破性療法。學術界、工業界和醫療保健提供者之間的合作促進跨學科研究工作，將科學發現轉化為臨床應用。然而，生物製藥和醫療創新帶來的高成本和漫長的開發時間、監管挑戰和生物技術產品嚴格的核准流程對市場成長構成了挑戰。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對紅色生物技術全球市場的各個細分市場進行了包容性評估。紅色生物技術產業的成長和趨勢為本研究提供了整體方法。

市場區隔

紅色生物技術市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略家確定相應產品或服務的目標人口統計數據以及即將到來的機會。

按產品分類

單株抗體
多株抗體抗體
重組蛋白
疫苗
基於細胞的免疫療法產品
基因治療產品
細胞治療產品
組織工程產品
幹細胞
細胞培養
病毒載體
酵素
試劑盒和試劑
動物模型
分子診斷
其他

按最終用戶

學術研究機構
CMO 和 CRO
製藥與生物技術公司
其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲紅色生物技術市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。紅色生物技術市場的主要參與者包括默克公司、羅氏公司、輝瑞公司、再生元製藥公司、阿斯特捷利康公司、武田製藥有限公司、吉利德科學公司、百健公司、安進公司、新基公司。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第8章：紅色生物科技公司的競爭格局

紅色生物科技市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Merck KGaA

公司概況
公司收入
產品
最新動態

F. Hoffmann-La Roche AG

公司概況
公司收入
產品
最新動態

Pfizer Inc.

公司概況
公司收入
產品
最新動態

Regeneron Pharmaceuticals Inc.

公司概況
公司收入
產品
最新動態

AstraZeneca Plc

公司概況
公司收入
產品
最新動態

Takeda Pharmaceutical Company Limited

公司概況
公司收入
產品
最新動態

Gilead Sciences

公司概況
公司收入
產品
最新動態

Biogen Inc.

公司概況
公司收入
產品
最新動態

Amgen Inc.

公司概況
公司收入
產品
最新動態

Celgene Corporation

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR11219534

The global demand for Red Biotechnology Market is presumed to reach the market size of nearly USD 1539.39 Billion by 2032 from USD 604.72 Billion in 2023 with a CAGR of 10.94% under the study period 2024-2032.

Red biotechnology, also known as medical biotechnology, is a branch of biotechnology focused on pharmaceuticals, medical devices, diagnostics, and healthcare solutions. Unlike green biotechnology (agricultural biotechnology) and white biotechnology (industrial biotechnology), it primarily targets medical and healthcare applications. It involves using biological processes, organisms, or systems to develop products and technologies to diagnose, prevent, and treat diseases and improve overall healthcare outcomes.

MARKET DYNAMICS

The global red biotechnology market is witnessing significant growth driven by the rising prevalence of chronic and infectious diseases worldwide. Red biotechnology is crucial in developing innovative therapies, vaccines, and diagnostic tools to address healthcare challenges associated with cancer, diabetes, cardiovascular disorders, and infectious diseases like COVID-19. Moreover, advancements in genomic research, personalized medicine, and biopharmaceuticals are fuelling market growth. Technologies such as gene editing, recombinant DNA technology, and monoclonal antibodies enable targeted and customized approaches to healthcare, enhancing treatment efficacy and patient outcomes.

Furthermore, increasing investments in research & development (R&D) by pharmaceutical companies, academic institutions, and government organizations drive innovation in red biotechnology. These investments support the discovery of novel drug candidates, biomarkers for disease diagnosis, and breakthrough therapies that leverage biotechnological advancements. Collaborations between academia, industry, and healthcare providers foster interdisciplinary research efforts to translate scientific discoveries into clinical applications. However, the high cost and lengthy development timelines associated with bringing biopharmaceuticals and medical innovations, regulatory challenges & stringent approval processes for biotechnological products pose a challenge to market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Red Biotechnology. The growth and trends of Red Biotechnology industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Red Biotechnology market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

Monoclonal Antibodies
Polyclonal Antibodies
Recombinant Proteins
Vaccines
Cell-Based Immunotherapy Products
Gene Therapy Products
Cell Therapy Products
Tissue-Engineered Products
Stem Cells
Cell Culture
Viral Vector
Enzymes
Kits and Reagents
Animal models
Molecular diagnostics
Others

By End-User

Academic Research Institutes
CMOs & CROs
Pharmaceutical & Biotechnology Companies
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Red Biotechnology market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Red Biotechnology market include Merck KGaA, F. Hoffmann-La Roche AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Gilead Sciences, Biogen Inc., Amgen Inc., Celgene Corporation. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. RED BIOTECHNOLOGY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By End-User
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL RED BIOTECHNOLOGY MARKET ANALYSIS BY PRODUCT

5.1. Overview By Product
5.2. Historical and Forecast Data Analysis By Product
5.3. Monoclonal Antibodies Historic and Forecast Sales By Regions
5.4. Polyclonal Antibodies Historic and Forecast Sales By Regions
5.5. Recombinant Proteins Historic and Forecast Sales By Regions
5.6. Vaccines Historic and Forecast Sales By Regions
5.7. Cell-Based Immunotherapy Products Historic and Forecast Sales By Regions
5.8. Gene Therapy Products Historic and Forecast Sales By Regions
5.9. Cell Therapy Products Historic and Forecast Sales By Regions
5.10. Tissue-Engineered Products Historic and Forecast Sales By Regions
5.11. Stem Cells Historic and Forecast Sales By Regions
5.12. Cell Culture Historic and Forecast Sales By Regions
5.13. Viral Vector Historic and Forecast Sales By Regions
5.14. Enzymes Historic and Forecast Sales By Regions
5.15. Kits and Reagents Historic and Forecast Sales By Regions
5.16. Animal models Historic and Forecast Sales By Regions
5.17. Molecular diagnostics Historic and Forecast Sales By Regions
5.18. Others Historic and Forecast Sales By Regions

6. GLOBAL RED BIOTECHNOLOGY MARKET ANALYSIS BY END-USER

6.1. Overview By End-User
6.2. Historical and Forecast Data Analysis By End-User
6.3. Academic Research Institutes Historic and Forecast Sales By Regions
6.4. CMOs & CROs Historic and Forecast Sales By Regions
6.5. Pharmaceutical & Biotechnology Companies Historic and Forecast Sales By Regions
6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL RED BIOTECHNOLOGY MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE RED BIOTECHNOLOGY COMPANIES

8.1. Red Biotechnology Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF RED BIOTECHNOLOGY INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Merck KGaA
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. F. Hoffmann-La Roche AG
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Pfizer Inc.
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Regeneron Pharmaceuticals Inc.
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. AstraZeneca Plc
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. Takeda Pharmaceutical Company Limited
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Gilead Sciences
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Biogen Inc.
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Amgen Inc.
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. Celgene Corporation
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments